The performance of NRx Pharmaceuticals stock continues to fall throughout the year. Since the beginning of the year, the price has fallen from $58.74 to $8.46. The stock price in the pre-market fell by 6.62% and is worth $7.90. Recently, NRX Pharmaceuticals (NXP) presented information on the safety of the drug ZYESAMI (aviptadil), which is being tested in the ACTIV-3b Phase 3 intensive care study sponsored by the National Institutes of Health.
In its second planned analysis, the Independent Data Security Monitoring Board of the study found no new safety concerns after reviewing a total of 231 patients and recommended continued enrollment. After reviewing 232 Registered patients in the ACTIVE-3b Intensive Care Study, the Independent Data Security Monitoring Commission did not identify any new safety issues, reviewing 232 registered patients in the intensive care study. ACTIV-3b is a ZYESAMI ™ study in severe or critical CAVID-19 patients who require high-flow supplemental oxygen supplied by nasal cannula, artificial lung ventilation, or extracorporeal membrane oxygenation.